QuidelOrtho Corp — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 62/100
What the filing says
QuidelOrtho reported Q3 2026 total revenue of $619M (down 12% YoY), with significant headwinds from China IVD pricing changes and weak respiratory season. The company announced a cost transformation program targeting $80M annual savings in 2027, with $30–35M one-time restructuring charges in Q4 2026. Full-year 2026 guidance was narrowed: revenues $2.52–2.54B (prior $2.52–2.60B), adjusted EBITDA $540–545M (prior $540–560M), adjusted diluted EPS $0.65–0.70 (prior $0.65–0.90).
Why this rating
Material 12% revenue decline and guidance cut (4–5% midpoint reduction) are significant for $1.9B company. Restructuring saves ~4% of annual revenue but signals operational stress, though underlying non-China/respiratory business grew 3%—offsetting headwinds partially mitigates severity.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.